Former Chief Executive Officer · IRONWOOD PHARMACEUTICALS INC (IRWD)

Mark Mallon

A named executive officer of IRONWOOD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2019 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$170,576

Salary $163,413Stock awards $0

FY2020: $6,821,113

7th of 7 named executive officers at Ironwood Pharmaceuticals by FY2021 total.

7 named officers on file for IRONWOOD PHARMACEUTICALS, FY2021

Mark Mallon’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • IRWD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IRONWOOD PHARMACEUTICALS’s whole pay program stands against its peers

  • IRONWOOD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IRWD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2022 (DEF 14A).

Free

Get Mark Mallon’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Mallon compensation by year

IRONWOOD PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as IRONWOOD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021
Salary$750,000$801,173$163,413
Bonus$880,000——
Stock awards$3,692,810$5,423,731$0
Option awards$3,804,331$0$0
Non-equity incentive$797,063$585,169$0
Pension and deferred compensation$0$0$0
All other$144,596$11,040$7,163
Total$10,068,800$6,821,113$170,576

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IRONWOOD PHARMACEUTICALS INC DEF 14A filed April 21, 2022, accession 0001104659-22-048389, and prior-year filings.

How this page was built: the IRONWOOD PHARMACEUTICALS INC filed document, accession 0001104659-22-048389. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2022.

$10.1M
$6.8M
$171K
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU311,409$4,144,854—
Option192,729—$10.97
Option423,049—$14.02

Per the Outstanding Equity Awards at Fiscal Year-End table in IRONWOOD PHARMACEUTICALS INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

IRONWOOD PHARMACEUTICALS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Thomas McCourtChief Executive Officer$8,810,004
Jason RickardSenior Vice President, Chief Operating Officer$3,479,230
John MinardoSenior Vice President, Chief Legal Officer and Secretary$3,148,293
Gina ConsylmanFormer Senior Vice President, Chief Financial Officer$2,792,880
Michael ShetzlineSenior Vice President, Chief Medical Officer and Head of Research and Drug Development$2,635,873
Sravan EmanySenior Vice President, Chief Financial Officer$2,528,992
Mark Mallon · this pageFormer Chief Executive Officer$170,576

The full IRONWOOD PHARMACEUTICALS compensation record

free company brief

This page is one person within IRONWOOD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IRONWOOD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IRONWOOD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Mallon's compensation dossier · One-time report. No refunds.